307 related articles for article (PubMed ID: 29315315)
1. Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy.
Lollert A; Stihl C; Hötker AM; Mengel E; König J; Laudemann K; Gökce S; Düber C; Staatz G
PLoS One; 2018; 13(1):e0190784. PubMed ID: 29315315
[TBL] [Abstract][Full Text] [Related]
2. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
3. Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles.
Nuñez-Peralta C; Alonso-Pérez J; Llauger J; Segovia S; Montesinos P; Belmonte I; Pedrosa I; Montiel E; Alonso-Jiménez A; Sánchez-González J; Martínez-Noguera A; Illa I; Díaz-Manera J
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):1032-1046. PubMed ID: 32129012
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
Strothotte S; Strigl-Pill N; Grunert B; Kornblum C; Eger K; Wessig C; Deschauer M; Breunig F; Glocker FX; Vielhaber S; Brejova A; Hilz M; Reiners K; Müller-Felber W; Mengel E; Spranger M; Schoser B
J Neurol; 2010 Jan; 257(1):91-7. PubMed ID: 19649685
[TBL] [Abstract][Full Text] [Related]
5. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.
Regnery C; Kornblum C; Hanisch F; Vielhaber S; Strigl-Pill N; Grunert B; Müller-Felber W; Glocker FX; Spranger M; Deschauer M; Mengel E; Schoser B
J Inherit Metab Dis; 2012 Sep; 35(5):837-45. PubMed ID: 22290025
[TBL] [Abstract][Full Text] [Related]
6. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.
Kuperus E; Kruijshaar ME; Wens SCA; de Vries JM; Favejee MM; van der Meijden JC; Rizopoulos D; Brusse E; van Doorn PA; van der Ploeg AT; van der Beek NAME
Neurology; 2017 Dec; 89(23):2365-2373. PubMed ID: 29117951
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
[TBL] [Abstract][Full Text] [Related]
8. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
Rafael Bretón Martínez J; Martínez AC
J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
[No Abstract] [Full Text] [Related]
9. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients.
Carlier PG; Azzabou N; de Sousa PL; Hicks A; Boisserie JM; Amadon A; Carlier RY; Wary C; Orlikowski D; Laforêt P
J Inherit Metab Dis; 2015 May; 38(3):565-72. PubMed ID: 25749708
[TBL] [Abstract][Full Text] [Related]
11. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
Semplicini C; De Antonio M; Taouagh N; Béhin A; Bouhour F; Echaniz-Laguna A; Magot A; Nadaj-Pakleza A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Tard C; Zagnoli F; Hogrel JY; Hamroun D; Laforêt P;
J Inherit Metab Dis; 2020 Nov; 43(6):1219-1231. PubMed ID: 32515844
[TBL] [Abstract][Full Text] [Related]
12. A novel mutation of the GAA gene in a Finnish late-onset Pompe disease patient: clinical phenotype and follow-up with enzyme replacement therapy.
Korpela MP; Paetau A; Löfberg MI; Timonen MH; Lamminen AE; Kiuru-Enari SM
Muscle Nerve; 2009 Jul; 40(1):143-8. PubMed ID: 19472353
[TBL] [Abstract][Full Text] [Related]
13. Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.
Tard C; Bouhour F; Michaud M; Beltran S; Fournier M; Demurger F; Lagrange E; Nollet S; Sacconi S; Noury JB; Magot A; Cintas P; Renard D; Deibener-Kaminsky J; Lefeuvre C; Davion JB; Salort-Campana E; Arrassi A; Taouagh N; Spinazzi M; ; Attarian S; Laforêt P
Eur J Neurol; 2024 Jul; 31(7):e16292. PubMed ID: 38587143
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
[TBL] [Abstract][Full Text] [Related]
15. [Guidelines for monitoring late-onset Pompe disease.Sociedad Española de Medicina Interna (SEMI), Sociedad Española de Neurología (SEN) y Sociedad Española de Neumología y CirugíaTorácica (SEPAR)].
Gutiérrez-Rivas E; Illa I; Pascual-Pascual SI; Pérez-López J; Vílchez-Padilla JJ; Bautista-Lorite J; Barrot E; López de Munain A; ; ;
Rev Neurol; 2015 Apr; 60(7):321-8. PubMed ID: 25806482
[TBL] [Abstract][Full Text] [Related]
16. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
Schoser B; Stewart A; Kanters S; Hamed A; Jansen J; Chan K; Karamouzian M; Toscano A
J Neurol; 2017 Apr; 264(4):621-630. PubMed ID: 27372449
[TBL] [Abstract][Full Text] [Related]
17. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J; Kishnani PS; Kushlaf H; Ladha S; Mozaffar T; Straub V; Toscano A; van der Ploeg AT; Berger KI; Clemens PR; Chien YH; Day JW; Illarioshkin S; Roberts M; Attarian S; Borges JL; Bouhour F; Choi YC; Erdem-Ozdamar S; Goker-Alpan O; Kostera-Pruszczyk A; Haack KA; Hug C; Huynh-Ba O; Johnson J; Thibault N; Zhou T; Dimachkie MM; Schoser B;
Lancet Neurol; 2021 Dec; 20(12):1012-1026. PubMed ID: 34800399
[TBL] [Abstract][Full Text] [Related]
19. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.
van der Ploeg AT; Barohn R; Carlson L; Charrow J; Clemens PR; Hopkin RJ; Kishnani PS; Laforêt P; Morgan C; Nations S; Pestronk A; Plotkin H; Rosenbloom BE; Sims KB; Tsao E
Mol Genet Metab; 2012 Nov; 107(3):456-61. PubMed ID: 23031366
[TBL] [Abstract][Full Text] [Related]
20. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
